Diagnos Inc. Engages Investor Brand Network for Enhanced Corporate Communications

Diagnos Inc. (TSX Venture: ADK) (OTCQB: DGNOF) (FWB: 4D4A), a Canadian corporation focused on early detection of critical health issues using artificial intelligence technology, has announced a strategic engagement with Investor Brand Network for corporate communication and awareness solutions. This partnership, effective January 10, 2026, represents a significant step in the company's efforts to enhance its market presence and maximize shareholder value through professional communications support. The one-year agreement involves monthly compensation of US$6,400 payable in advance from the corporation's funds, with IBN acting at arm's length and holding no direct or indirect interest in Diagnos securities.

The engagement with IBN is particularly important for Diagnos as it seeks to expand awareness of its AI-based technology platform designed to detect critical eye-related health problems at early stages. By leveraging artificial intelligence, the company aims to provide healthcare clinicians with enhanced diagnostic tools that improve accuracy, streamline workflows, and ultimately lead to better patient outcomes globally. The corporate communications support from IBN will help communicate these technological advancements and their potential impact on healthcare systems to investors and the broader market.

Investor Brand Network brings substantial communications expertise to this partnership, operating as a specialized platform within the Dynamic Brand Portfolio that includes more than 75 brands. IBN's services encompass advanced wire-grade press release syndication, article and editorial distribution to over 5,000 outlets, enhanced press release optimization, and comprehensive social media distribution through its network of millions of followers. This multifaceted approach ensures that Diagnos's corporate messaging reaches diverse target markets, demographics, and industry sectors effectively.

The timing of this engagement coincides with increasing investor interest in healthcare technology companies developing AI solutions for medical diagnostics. As Diagnos continues to advance its technology platform, effective communication of milestones, clinical validations, and market developments becomes increasingly crucial for maintaining investor confidence and attracting new investment. The company's focus on early detection of eye-related conditions addresses a significant healthcare need, given that many vision-threatening conditions show minimal symptoms until irreversible damage has occurred.

Additional information about Diagnos is available through its corporate website at https://www.diagnos.com and regulatory filings accessible via https://www.sedarplus.com. The engagement remains subject to acceptance by the TSX Venture Exchange, reflecting standard regulatory oversight for publicly traded companies entering into material agreements. This corporate communications partnership represents a strategic investment in Diagnos's growth trajectory as it positions itself within the competitive landscape of AI-driven healthcare solutions.